OmniAb appointed Amechi Nwachuku as Chief Operating Officer, effective July 13, 2026.
| IndividualAmechi Nwachuku | RoleChief Operating Officer | Type of ChangeAppointed | Effective DateJuly 13, 2026 | ReasonNot disclosed | Replacement InfoNot disclosed | Background DetailsGlobal life sciences executive; prior roles include Thermo Fisher (VP Global Commercial, Genetic Sciences), SCIEX (SVP Global Commercial), Beckman Coulter Diagnostics, Johnson & Johnson Diabetes Care, and Bayer; MBA and BS from MIT. | Board/Committee Role ChangesNot disclosed | Compensation - Base Salary$445,000 initial annual base salary | Compensation - BonusAnnual target bonus 45% of base salary (prorated for 2026); $20,000 signing bonus | EquityGrant of options to purchase 800,000 shares effective August 1, 2026; vesting over 4 years with 12.5% at 6 months, then monthly vesting; exercise price = Nasdaq closing price on grant date | Severance PlanEligible under OmniAb Severance Plan: cash equal to base salary for severance period (2 months + 1 week per year of service) and COBRA health coverage during severance; payable upon release execution | Change-in-Control SeveranceIf terminated without cause or resigns for good reason within 24 months after change in control: lump sum equal to 1x base salary + 1x greater of max target bonus (current or at change in control) + 12x monthly health premium; time-based stock awards vest and option post-termination exercise period extended to 9 months (subject to original expiration) |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.